Friday 21st March - Main Conference Day Three - PT (Pacific Time, GMT-08:00)
- Landon Mott - Process Development Principal Scientist, Amgen Inc.
- Allyn Spear - Principal Research Scientist, Cell Line Development Lead, Elanco Animal Health
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: Partners@informaconnectls.com
- Frank Ritacco, PhD - Senior Director, Cell Culture Development, Regeneron
Knock out (KO) of the BCAT1 gene encoding the first enzyme in the BCAA catabolic pathway reduces accumulation of growth inhibitory short chain fatty acid (SCFA) by-products1. Some accumulation of these SCFAs, however, allows for robust metabolic shift and higher specific productivities2. This talk describes the development of a next-gen process using high-end pH-controlled delivery of glucose (HiPDOG) technology combined with SCFA addition to improve productivity in fed-batch culture.
- Maddie Andres - Senior Associate Scientist, Pfizer
The biopharmaceutical industry faces increasing pressure to produce a wide range of therapeutics quickly, with high yields and consistent quality. Lonza helps companies meet these demands with integrated solutions that streamline the entire drug development process. By combining cutting-edge expression technology, efficient CHO media systems, and expert biologics services, we support drug developers and producers from late-stage discovery all the way to commercial supply.
At the core of our solutions is the proven GS® platform, designed to deliver high-yield, scalable, and stable expression for a broad range of biotherapeutics. With this platform, we help you optimize the expression of your molecule, whatever its type, helping to reduce time to market.
Supporting this, the TheraPRO® CHO Media System offers a chemically defined, non-animal origin (NAO) formulation, solution engineered to maximize protein yield and ensure scalability across research and manufacturing stages. Its advanced formulation delivers consistent performance and simplifies workflows, backed by proven performance for modern bioprocessing needs.
Lonza’s biologics services further offer end-to-end solutions for any molecule type. These services encompass drug candidate selection & optimization, process development, clinical and commercial manufacturing, and regulatory support, helping customers reach the clinic and market faster.
In this talk, we'll cover how our proven GS® platform, CHO media, and expertise in biologics enable biopharmaceutical companies to efficiently bring scalable, high-quality therapies to market, transforming scientific innovation into life-changing treatments for patients.
- Sanjay Kumar - Head of Technical Excellence, Media Solutions, Lonza Bioscience
- Julie Beaudet - CMC Sr. Staff Scientist, Regeneron
- Semsi Ensari - Sr Director, Process Development, Kite Pharma
- Brian Wong - Associate Director, Cell Culture Media, Upside Foods
Innovation to upstream process development has led to higher cell culture titers of biotherapeutics, the increased titer levels have placed a greater challenge to downstream processing to operate more efficiently and reduce cost. To purify increasing amounts of biotherapeutics more efficiently, the use of high flow rates or greater resin-bed heights during downstream chromatography steps is an alluring option. A limitation of increasing chromatography flow rates is the back pressure generated by compression of the packed chromatography resin beds. As chromatography column diameter and resin bed height increases, the resin bed is susceptible to compression that reduces the permeability of the packed resin bed. By providing support of the packed resin bed through control of the hydraulic radius, the permeability of a packed resin bed can be maintained during scale up of the chromatography column. The greater the permeability of a packed resin bed, column pressure-flow dynamics can be improved. Here we introduce OMEGA, a chromatography column insert designed to modulate the hydraulic radius of the column by providing vertical supports through the packed resin bed. Using a commercially available protein A resin, chromatography column performance with and without OMEGA was assessed. OMEGA reduces the effective hydraulic radius of packed columns and increases the permeability of packed resin bed. OMEGA enables higher operational flow rates at increased resin bed height without impact to either dynamic binding capacity or purified product quality. Through the use of OMEGA, scale up hurdles are mitigated, and faster downstream processing times are unlocked across column geometries.
- Romone Fancy, PhD - Process Development Scientist II/Project Leader, Downstream Process Development, KBI BioPharma
- Jolene Ignowski, Ph.D - CMC Project Lead, Bayer
- Stefano Menegatti - Associate Professor, North Carolina State University
- Managing resin saturation and desaturation cycles when implementing a continuous processing approach within downstream;
- Can upstream and downstream operations be combined for a seamless workflow?
- Utilising PAT for real-time data and process control throughout production;
- Case-study examples and data: how has continuous been implemented and what happened?
- Jean-Marc Cappia - Head of Market Development, Intensified Chromatography, Separation Technologies, Sartorius
- Manuel Carrondo - Vice-President, Instituto de Biologia Experimental e Tecnológica
- Justin Skoble - Vice President, Caribou Biosciences, Inc.
- Jitendra Kumar - Lead Scientist - Chemistry & Process Development, Entos Pharmaceuticals Inc.
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: Partners@informaconnectls.com
- Macroeconomic factors: Funding environment and the new US administration.
- After several years of funding headwinds, is the money back and if so where? How is this therefore affecting the services sectors?
- Two months in, and how are Trump's policies and tariff threats affecting the pharma supply chain and biomanufacturing investments both in the US and elsewhere.
- China
- What are the repercussions (if any!) of BIOSECURE on the CDMO space?
- How are continued supply chain challenges in China affecting the vendor side
- Capacity concerns in the outsourcing space
- Where are the current capacity gaps, and what is being done to relieve them?
- Viral vector report: Is demand for CGTs matching the supply avenues?
- Dealmaking
- How are biopharma M&A trends hitting service firms?
- How are CDMO and vendor acquisitions changing the dynamics in the industry?
- CDMO differentiators: How fragmented is the industry and what are CDMOs doing to raise their heads above the contractor parapet?
- Dan Stanton - Editorial Director, Informa Connect Life Sciences
- Andrew Harmon - Associate Manager, Management & Strategy Consulting, Sia Partners
- Macroeconomic factors: Funding environment and the new US administration.
- After several years of funding headwinds, is the money back and if so where? How is this therefore affecting the services sectors?
- Two months in, and how are Trump's policies and tariff threats affecting the pharma supply chain and biomanufacturing investments both in the US and elsewhere.
- China
- What are the repercussions (if any!) of BIOSECURE on the CDMO space?
- How are continued supply chain challenges in China affecting the vendor side
- Capacity concerns in the outsourcing space
- Where are the current capacity gaps, and what is being done to relieve them?
- Viral vector report: Is demand for CGTs matching the supply avenues?
- Dealmaking
- How are biopharma M&A trends hitting service firms?
- How are CDMO and vendor acquisitions changing the dynamics in the industry?
- CDMO differentiators: How fragmented is the industry and what are CDMOs doing to raise their heads above the contractor parapet?
- Dan Stanton - Editorial Director, Informa Connect Life Sciences
- Andrew Harmon - Associate Manager, Management & Strategy Consulting, Sia Partners
Get ready for a dynamic session showcasing the latest breakthroughs in bioprocessing. Experts will deliver short, impactful presentations on game-changing data strategies and innovative equipment, providing valuable insights for researchers and industry professionals.
Catriona Crombie, Associate Director for Technology Transfer and Rare Disease Challenge Lead, LifeArc
- Laura Zielewicz - Senior Scientist, Pfizer
- Bin Fan, PhD - Director of Biologics, NGM Biopharmaceuticals
HEK293 cells have emerged as a vital platform for producing recombinant therapeutic proteins, primarily due to their ability to closely replicate human post-translational modifications (PTMs). This results in biologically active proteins that are more human-like, offering distinct advantages over alternative production systems. ExcellGene's HEK293Express-based cell lines distinguish themselves with their fast growth, robust characteristics, and high protein yield and functionality, making them attractive choice for large-scale industrial applications.
In this presentation, we will delve into key experiments that have been crucial in optimizing the development of HEKExpress-based cell lines, covering transfection, stable pool selection, and the generation and assessment of stable clones. We will also present case studies that highlight the benefits of utilizing HEKExpress-based cell line development platform at ExcellGene.
- Danijel Svec - Senior Cell Line Development Associate & Project Team Leader, ExcellGene SA
How it will work is we have 3 Round Tables each covering a different Emerging Innovation in Upstream Bioprocessing. Each will be led by an expert. The expert will kick off and guide the discussion which will last for 30 minutes. At the end of the 30 minutes the leader will report their main conclusions to the room for a maximum of 10 minutes.
Continuous and Intensified Processing
- Transitioning from traditional batch to continuous systems.
- Integration with downstream processes.
- Regulatory acceptance and validation hurdles.
- Development of hybrid systems for phased implementation.
- Advances in perfusion systems and single-use bioreactors.
- Widespread adoption in commercial manufacturing.
- Improved efficiency, reduced costs, and faster time to market.
Automation and AI in Cell Culture
- Resistance to adopting AI-driven systems.
- Lack of data standardization and integration.
- Implementation of user-friendly AI tools with robust training programs.
- Standardized data frameworks and digital transformation strategies.
- Collaboration between tech companies and biopharma.
- Fully automated bioprocessing plants.
- Predictive analytics and AI-driven decision-making becoming mainstream.
Cell Line Engineering Advances
- Genetic stability and regulatory concerns with novel cell lines.
- Slow timelines for new cell line development.
- Limited understanding of long-term impacts of gene editing.
- Use of CRISPR and synthetic biology for targeted, efficient modifications.
- High-throughput screening to accelerate selection.
- Emergence of designer cell lines for specific therapies.
- Nathan Lewis, PhD - Professor, University of California, San Diego
- Ken Lee - Director, Bioprocess Technologies and Engineering, BioPharmaceuticals Development, R&D, AstraZeneca
- David Wood - Professor of Chemical and Biomolecular Engineering, Ohio State University
- Marion Jenny - MSAT Senior Scientist (DSP), MeiraGTx
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: Partners@informaconnectls.com
- David Wood - Professor of Chemical and Biomolecular Engineering, Ohio State University
- Marion Jenny - MSAT Senior Scientist (DSP), MeiraGTx
- Dan Oliver - CEO and Founder, Rejuvenate Bio, USA
- Panos Chrysanthopoulos - Chief Development Officer, Morphocell
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: Partners@informaconnectls.com
Ciaran Brady, Vice President – Manufacturing Science and Technology (MS&T), Vertex Pharmaceuticals Inc.
- Cheryl Scott - Editor in Chief, BioProcess International
- Eashwar Rajaraman - Principal Scientist I, Novartis
- Annabel Johnson - Principal Scientist, Johnson & Johnson
- Katherine Resch - Process Characterization and Technology, Regeneron
Maximize your time at BPI West by diving into the heart of innovation! Explore the hottest in cutting-edge bioprocessing in our bustling exhibition hall, where you'll discover the latest technologies and solutions from industry leaders. Beyond the booths, don't miss our exclusive meet the machines tours. These immersive experiences offer real-world demonstrations of ground-breaking technologies and innovations, giving you a first-hand look at how they can revolutionize your work. It's the perfect opportunity to connect with experts, ask questions, and gain valuable insights you won't find anywhere else.
Engage in focused discussions and connect with peers during our exclusive roundtable sessions. These intimate, 30-minute gatherings offer BPI readers the chance to delve into critical industry topics alongside expert leaders. Choose from five dynamic roundtables covering: Cell Line Development, Upstream Processing, Recovery & Purification, Manufacturing Strategy & Digitalization, and the cutting-edge field of Cell & Gene Therapy. Each table will be hosted by a prominent industry figure, facilitating open conversation and allowing you to share your challenges, gain valuable insights, and network with fellow attendees facing similar hurdles. Space is limited, so be sure to get there early for these invaluable peer-to-peer learning opportunities.
- Cheryl Scott - Editor in Chief, BioProcess International
- Eashwar Rajaraman - Principal Scientist I, Novartis
- Annabel Johnson - Principal Scientist, Johnson & Johnson
- Katherine Resch - Process Characterization and Technology, Regeneron
- Vivek Natarajan - AI Research Lead, Google Research
- Veena Warikoo - VP, Global Technical Operations, AstraZeneca